Fatty Liver Disease Explainer
Fatty liver disease describes excess fat accumulating in liver cells. It is now often discussed under the broader term steatotic liver disease. One important form is metabolic dysfunction-associated steatotic liver disease, or MASLD, which replaced the older name nonalcoholic fatty liver disease in newer terminology. Alcohol-associated liver disease is another important cause of fat buildup. The name alone does not establish the cause or severity. Assessment considers metabolic health, alcohol exposure, medicines, and other possible liver conditions rather than assuming every case follows the same pathway.
Fat in the liver and progressive liver damage are related but different findings. Some people have fat accumulation with little inflammation, while others develop metabolic dysfunction-associated steatohepatitis, or MASH, formerly called NASH. In that form, inflammation and liver cell injury can lead to fibrosis, which means scarring. Advanced scarring can progress to cirrhosis. This does not mean everyone with fat visible on a scan will develop severe disease. The key clinical question is which people have significant injury or a greater risk of progression.
The condition often causes few or no symptoms and may be noticed during blood tests or imaging for another reason. Evaluation can include a history, examination, blood tests, and liver imaging. Ordinary imaging may show fat without establishing how much inflammation or scarring is present. Other assessments, including tests of liver stiffness, can help evaluate fibrosis. A biopsy is sometimes used for a more specific question, but it is not needed for every person. A single liver enzyme result is not a complete assessment of liver health.
Care depends on the form and severity of disease and the person’s wider health. Nutrition, physical activity, suitable weight management, and treatment of associated metabolic conditions can be important parts of a plan. Alcohol exposure should be discussed honestly because it influences both diagnosis and advice. Specialist treatment may be appropriate for selected cases. Follow-up matters even when a person feels well. Understanding the distinction between fat, inflammation, and scarring helps readers see why similar-sounding scan results can lead to different recommendations.
The liver processes nutrients and stores energy, so its relationship with metabolic health is important. Type 2 diabetes, abnormal blood fats, and other metabolic factors can accompany MASLD. These associations help guide evaluation but do not explain every individual case. Fat buildup can have more than one contributing cause, and a useful history includes alcohol, medicines, and other conditions.
Older records may use NAFLD and NASH, while newer discussions use MASLD and MASH. The newer language emphasizes metabolic dysfunction and changes how categories are described. Seeing an older term does not mean that a past scan has changed. Readers should ask which condition the clinician means and whether the terminology affects the interpretation of their own medical history.
Blood tests can identify signs of injury or help assess other explanations, but they do not by themselves measure all aspects of liver damage. Imaging tests also differ in what they show. A scan showing fat should be connected with clinical risk factors and other findings. The presence of a visible finding does not automatically reveal how the condition will behave over time.
Elastography estimates liver stiffness, which can help assess fibrosis. A clinician may combine it with blood-based assessments and sometimes a biopsy when the answer would change care. Each test has limits and must be interpreted in context. Explaining the question behind a test is more useful than treating one method as mandatory for everyone with suspected fatty liver disease.
A management plan can connect liver health with the treatment of diabetes, blood pressure, and other metabolic concerns. Changes should be appropriate to the person’s circumstances and sustainable over time. Rapid or extreme dieting is not a substitute for a monitored plan. Medicines, supplements, and alcohol use should be discussed so that the team has an accurate picture of relevant exposures.
Follow-up can reassess risk and response even when there are no obvious symptoms. The aim is to recognize and reduce the chance of progressive damage while addressing broader health needs. New symptoms, unexpected test results, or difficulty following the plan warrant discussion. A label such as fatty liver is the beginning of an assessment, not a complete prognosis.
Explore more "Explainers"
Discover additional explainers across politics, science, business, technology, and other fields. Each explainer breaks down a complex idea into clear, everyday language—helping you better understand how major concepts, systems, and debates shape the world around us.